• Análise de custo-efetividade de formoterol associado à budesonida para terapia de manutenção e alívio (Symbicort SMART) versus salmeterol associado à fluticasona no tratamento da asma persistente moderada a grave sob a perspectiva brasileira

  • Voltar

Título

Análise de custo-efetividade de formoterol associado à budesonida para terapia de manutenção e alívio (Symbicort SMART) versus salmeterol associado à fluticasona no tratamento da asma persistente moderada a grave sob a perspectiva brasileira

Tipo de documento

Apresentação

Descrição

Resumo apresentado na The Professional Society for Health Economics and Outcomes Research (ISPOR)

Fonte

ISPOR

Ano de publicação

2009

Referência (Vancouver)

Teich V, Niskier F, Pimentel A, Alameddine M. Cost-effectiveness analysis of formoterol associated to budesonide for maintenance and reliever therapy (symbicort smart) versus salmeterol associated to fluticasone in the treatment of moderate to severe persistent asthma under the Brazilian [Internet]. In: ISPOR Europe 2009; Paris, France. Disponível em: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-12th-annual-european-congress/cost-effectiveness-analysis-of-formoterol-associated-to-budesonide-for-maintenance-and-reliever-therapy-symbicort-smart-versus-salmeterol-associated-to-fluticasone-in-the-treatment-of-moderate-to-severe-persistent-asthma-under-the-brazilian

URL

https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-12th-annual-european-congress/cost-effectiveness-analysis-of-formoterol-associated-to-budesonide-for-maintenance-and-reliever-therapy-symbicort-smart-versus-salmeterol-associated-to-fluticasone-in-the-treatment-of-moderate-to-severe-persistent-asthma-under-the-brazilian

Identificador

2009ISPOR066

Title

Cost-effectiveness Analysis of Formoterol Associated to Budesonide For Maintenance and Reliever Therapy (symbicort Smart) Versus Salmeterol Associated to Fluticasone in the Treatment of Moderate to Severe Persistent Asthma Under the Brazilian Perspective

Document type

Presentation

Description

Abstract presented at The Professional Society for Health Economics and Outcomes Research (ISPOR)

Source

ISPOR

Publication year

2009

Reference (Vancouver)

Teich V, Niskier F, Pimentel A, Alameddine M. Cost-effectiveness analysis of formoterol associated to budesonide for maintenance and reliever therapy (symbicort smart) versus salmeterol associated to fluticasone in the treatment of moderate to severe persistent asthma under the Brazilian [Internet]. In: ISPOR Europe 2009; Paris, France. Available from: https\://www\.ispor.org/heor-resources/presentations-database/presentation/ispor-12th-annual-european-congress/cost-effectiveness-analysis-of-formoterol-associated-to-budesonide-for-maintenance-and-reliever-therapy-symbicort-smart-versus-salmeterol-associated-to-fluticasone-in-the-treatment-of-moderate-to-severe-persistent-asthma-under-the-brazilian

URL

https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-12th-annual-european-congress/cost-effectiveness-analysis-of-formoterol-associated-to-budesonide-for-maintenance-and-reliever-therapy-symbicort-smart-versus-salmeterol-associated-to-fluticasone-in-the-treatment-of-moderate-to-severe-persistent-asthma-under-the-brazilian

Identifier

2009ISPOR066

Resumo

Objetivos: Desenvolver uma análise de custo-efetividade da associação de formoterol com budesonida para terapia de manutenção e alívio (FB SMART) versus salmeterol associado a fluticasona (SF) no tratamento de pacientes com asma persistente moderada a grave, sob a perspectiva da sociedade Brasileira. Métodos: Um modelo de Markov foi desenvolvido para projetar custos e resultados associados à progressão da doença de pacientes com asma persistente moderada a grave recebendo terapia SMART ou SF em um horizonte de tempo de um ano. Foram considerados ciclos semanais e a estrutura do modelo consistia em quatro possíveis estados de saúde: controle da doença, uso de corticoides orais (CO), hospitalização/visita de emergência (H/ER) e morte. As probabilidades de ter exacerbações graves (CO ou H/ER) foram extraídas do estudo de Kuna et al. As taxas de mortalidade por todas as causas foram obtidas de bancos de dados epidemiológicos nacionais. Eventos adversos não foram significativamente diferentes entre os comparadores e foram excluídos do modelo. Os resultados foram expressos como exacerbações graves evitadas (SEA) e apenas custos médicos diretos foram incluídos na análise. O uso de recursos durante a hospitalização foi estimado com base em um painel de especialistas. Os preços máximos ao consumidor foram obtidos para medicamentos e os custos dos procedimentos foram extraídos da Classificação Brasileira de Procedimentos Médicos (CBHPM). Resultados: Em um ano, o número médio de exacerbações graves foi de 0,2436 no grupo SMART e 0,3928 no grupo SF, resultando em 0,1492 exacerbações graves evitadas. O custo total para os grupos SMART e SF foi de R$1823,56 e R$1417,49, respectivamente (custo incremental=R$406,07). A razão de custo-efetividade incremental em 1 ano foi de R$2721/SEA (US$1944, índice PPP 2005 USD1,0=R$1,4). As variáveis que mais influenciaram os resultados foram os custos da terapia SMART e SF e o custo da hospitalização. Conclusões: A terapia SMART reduz o risco de exacerbações graves em comparação com o SF em pacientes com asma persistente moderada a grave, com um custo incremental razoável, sendo uma alternativa valiosa para esses pacientes.

Notas

O registro foi originalmente publicado em inglês. A versão em português foi traduzida com o apoio de inteligência artificial.

Abstract

Objetives: To develop a cost-effectiveness analysis of formoterol associated to budesonide for maintenance and reliever therapy (FB SMART) versus salmeterol associated do fluticasone (SF) in the treatment of patients with moderate to severe persistent asthma, under the Brazilian societal perspective. Methods: A Markov model was developed to project costs and outcomes associated with disease progression of patients with moderate to severe persistent asthma receiving SMART therapy or SF in a one year time horizon. Weekly cycles were considered and the model structure consisted of four possible health states: disease control, use of oral corticoids (OC), hospitalization/emergency visit (H/ER) and death. The probabilities of having severe exacerbations (OC or H/ER) were extracted from the study by Kuna et al. All cause mortality rates were obtained from national epidemiological databases. Adverse events were not significantly different between comparators so were excluded from the model. Outcomes were expressed as severe exacerbations avoided (SEA) and only direct medical costs were included in the analysis. Resource use during hospitalization was estimated based on an expert panel. Maximum prices to consumer were obtained for drugs, and procedure costs were extracted from the Brazilian Classification of Medical Procedures (CBHPM). Results: In one year, the average number of severe exacerbations was 0.2436 in the SMART group and 0.3928 in the SF group, resulting in 0.1492 severe exacerbations avoided. Total cost for the SMART and SF groups were R$1823.56 and R$1417.49, respectively (incremental cost=R$406.07). The incremental cost-effectiveness ratio in 1 year was R$2721/SEA (US$1944 2005-PPP-index USD1.0=R$1.4). The variables that most influenced the Results were the costs of SMART and SF therapy and the cost of hospitalization. Conclusions: SMART therapy reduces the risk of severe exacerbations when compared to SF in patients with moderate to severe persistent asthma, at a reasonable incremental cost, being a valuable alternative for these patients.

Notes

The record was originally published in English. The Portuguese version was translated with the aid of artificial intelligence.

Continuar navegando